Overview

* Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss

* Company raised $2.3 mln through at-the-market facility, strengthening balance sheet

* Research and development expenses increased due to Phase 1 study costs

Outlook

* Indaptus expects current cash to support operations into Q1 2026

* Company is evaluating financing options to support its strategy

* Indaptus pauses trial enrollment pending further efficacy evaluations

Result Drivers

* BALANCE SHEET STRENGTHENED - Raised $2.3 mln through at-the-market facility

* R&D EXPENSES - Increase due to Phase 1 study costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat -$2.98 -$4.17

(1

Analyst)

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Indaptus Therapeutics Inc ( INDP ) is $25.00, about 89.1% above its November 11 closing price of $2.72

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)